Meta-analysis of the clinical effect of ligustrazine on diabetic nephropathy

American Journal of Chinese Medicine

Volumn 40, Issue 1, 2012, Pages 25-37

  Wang, Bin ^a   Ni, Qing ^a   Wang, Xun ^b   Lin, Lan ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Diabetic Nephropathy; Ligustrazine; Meta Analysis

Indexed keywords

ALBUMIN; CREATININE; TETRAMETHYLPYRAZINE;

ARTICLE; CREATININE BLOOD LEVEL; DATA BASE; DIABETIC NEPHROPATHY; HUMAN; KIDNEY FUNCTION; MEDICAL LITERATURE; META ANALYSIS; MICROALBUMINURIA; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINARY EXCRETION;

BLOOD UREA NITROGEN; CREATININE; DIABETIC NEPHROPATHIES; DRUGS, CHINESE HERBAL; HUMANS; KIDNEY; LIGUSTICUM; PHYTOTHERAPY; PROTEINURIA; PYRAZINES;

EID: 84863067048     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X12500036     Document Type: Article

References (48)

1. Cai, Y., J. Chen, J. Jiang, W. Cao and L. He. Zhen-wu-tang, a blended traditional Chinese herbal medicine, ameliorates proteinuria and renal damage of streptozotocin-induced diabetic nephropathy in rats. J. Ethnopharmacol. 131: 88-94, 2010.
2. Chen, X.D. Efficacy of Ligustrazine in the treatment of diabetic microalbuminuria. Youjiang Med. J. 33: 498-499, 2005.
3. Cui, Z., F. Chen, S.J. Gu and J.M. Lin. Effect of Ligustrazine on renal function and blood lipid in elderly diabetic nephropathy patients. People Mil. Surg. 49: 190-191, 2006.
4. Dai, X.Z. and R.J. Bache. Coronary and systemic hemodynamic effects of tetramethylpyrazine in the dog. J. Cardiovasc. Pharmacol. 7: 841-849, 1985. (Pubitemid 15235145)
5. Feng, L., Y. Xiong, F. Cheng, L. Zhang, S. Li and Y. Li. Effect of ligustrazine on ischemia-reperfusion injury in murine kidney. Transplant. Proc. 36: 1949-1951, 2004.
6. Fu, H., J. Li, Q.X. Li, L. Xia and L. Shao. Protective effect of ligustrazine on accelerated anti-glomerular basement membrane antibody nephritis in rats is based on its antioxidant properties. Eur. J. Pharmacol. 1563: 197-202, 2007. (Pubitemid 46602241)
7. He, S.P. and J.M. Ma. Effect of Ligustrazine in early diabetic nephropathy. Med. J. Chin. People Health 20: 2519-2520, 2008.
8. Ho, W.K., H.L. Wen and C.M. Lee. Tetramethylpyrazine for treatment of experimentally induced stroke in Mongolian gerbils. Stroke 20: 96-99, 1989. (Pubitemid 19040220)
9. Huang, J.Z. Efficacy of Ligustrazine injection in the management of diabetic nephropathy. China Pract. Med. l5: 44-45, 2010.
10. Huang, Y., S.Q. Chen, G. Zhang and R.H. Chen. Effect of tetromethylpyrazine and aminoguanidine on expression of vascular endothelial growth factor in kidney of diabetic rats. Zhong Xi Yi Jie He Xue Bao 2: 39-41, 2004.
11. Ke, L. and X.T. Li. Effect of Ligustrazine in diabetic nephropathy. J. Anhui Tradit. Chin. Med. Coll. 26: 6-8, 2007.
12. Lee, L.M., C.F. Liu and P.P. Yang. Effect of tetramethylpyrazine on lipid peroxidation in strepto-zotocin-induced diabetic mice. Am. J. Chin. Med. 30: 601-608, 2002.
13. Li, L.L., Z.R. Zhang, T. Gong, L.L. He and L. Deng. Simultaneous determination of gastrodin and Ligustrazine hydrochloride in dog plasma by gradient high-performance liquid chromatog-raphy. J. Pharm. Biomed. Anal. 41: 1083-1087, 2006. (Pubitemid 43792400)
14. Lin, L., X.Z. Guo and M. Li. Analysis on relationship of Chinese medicine syndrome pattern with urinary albumin excretion rate and its related factors in early stage diabetic nephropathy. Zhonggu Zhong Xi Yi Jie He Za Zhi 30: 912-914, 2010.
15. Lin, L., Q. Ni and Q.J. Gao. Observation on treatment of diabetic nephropathy by Tangweikang capsule. Zhongguo Zhong Xi Yi Jie He Za Zhi 8: 19-23, 2002.
16. Liu, Y.J. Efficacy of Ligustrazine injection in the treatment of diabetic nephropathy. China Natur-opath. 15: 38-39, 2007.
17. Ma, B.S. Clinical observation on treatment of early diabetic nephropathy by Ligustrazine injection. Acta Chin. Med. Pharmacol. 37: 73-74, 2009.
18. Mogensen, C.E., C.K. Christensen and E. Vittinghus. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32: 64-78, 1983.
19. Niu, Y.B. and C.Y. Yang. Clinical observation on treatment of early diabetic nephropathy with Ligustrazine injection. Chin. J. Curr. Clin. Med. 5: 629-630, 2007.
20. Nordquist, L. and J. Wahren. C-peptide: the missing link in diabetic nephropathy. Rev. Diabet. Stud. 6: 203-210, 2009.
21. Obineche, E.M. and A. Adem. Update in diabetic nephropathy. Int. J. Diabetes Metab. 13: 1-9, 2005.
22. Parving, H.H. Diabetic nephropathy: prevention and treatment. Kidney Int. 60: 2041-2055, 2001.
23. Pei, W. Effects on Ligustrazine injection in treating early diabetic nephropathy. J. Med. Forum 26: 71-72, 2005.
24. Pennel, J.P. and T.L. Meinking. Pattern of urinary proteins in experimental diabetes. Kidney Int. 21: 709-713, 1982. (Pubitemid 12124302)
25. Ren, Z., M.H. Guo and X.D. Liu. Efficacy of Ligustrazine injection in the treatments of clinical diabetic nephropathy. Chin. J. Clin. Pharmacol. Ther. 3: 227-228, 1998.
26. Shang, J.C. and F.Z. Xu. Effect of Ligustrazine on plasma endothelin and hemorheology in patients with diabetic nephropathy. J. West. China Med. 21: 388-389, 2009.
27. Sheu, J.R., Y.C. Kan, W.C. Hung, C.H. Lin and M.H. Yen. The antiplatelet activity of tetra-methylpyrazine is mediated through activation of NO synthase. Life Sci. 67: 937-947, 2000.
28. Siddiqui, S., M. Rashid Khan and W.A. Siddiqui. Comparative hypoglycemic and nephroprotective effects of tocotrienol rich fraction (TRF) from palm oil and rice bran oil against hyperglycemia induced nephropathy in type 1 diabetic rats. Chem. Biol. Interact. 188: 651-658, 2010.
29. Sun, W.W. Clinical observation on the therapeutic effect of Ligustrazine injection in treating diabetic nephropathy. Shanxi J. Tradit. Chin. Med. 24: 23-24, 2008.
30. Tan, X.Y. and X.H. Wang. Effect of Ligustrazine in early diabetic nephropathy. J. Qilu Med. 18: 46-47, 2003.
31. Tang, G.C., G.C. Lu and J.L. Wu. Effect of Ligustrazine on plasma endothelin in early diabetic nephropathy patients. Chin. J. Integr. Tradit. West. Nephrol. 2: 7-25, 2001.
32. Tian, X.W., D.G. Zhang, J.X. Cao and X.K. Li. Clinical observation on the therapeutic effect of Ligustrazine injection in early diabetic nephropathy patients. Chin. J. Med. Writ. 11: 195-197, 2004.
33. Viberti, G. and N.M. Wheeldon. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106: 672-678, 2002. (Pubitemid 34851925)
34. Wang, J.H. and S.D. Hui. Treatment of chronic complications of diabetes with Ligustrazine. Mod. J. Integr. Tradit. Chin. West. Med. 19: 1706-1708, 2010.
35. Wang, X.F. and H.Y. Wang. Effect of Ligustrazine in early diabetic nephropathy. J. Pract. Tradit. Chin. Intern. Med. 19: 172, 2005.
36. Wang, X.J., C.S. Liu, Y. Ming, L.P. Sun and H.X. Liu. Effect of Ligustrazine on the activity of aldose reductase and apoptosis in diabetic rat. China J. Tradit. Chin. Med. Pharm. (suppl): 55-57, 2009.
37. Wen, X.G., D.Z. Wang, Q.G. Zhang, X.H. Suo and Y.N. Guo. Effect of Ligustrazine in early diabetic nephropathy. J. Xinxiang Med. Coll. 12: 150-153, 1995.
38. Yan, L.G., Y. Lu, S.Z. Zheng, A.Y. Wang, M.Q. Li, J.S. Ruan and L. Zhang. Injectable caltrop fruit saponin protects against ischemia-reperfusion injury in rat brain. Am. J. Chin. Med. 39: 325-333, 2011.
39. Yang, Y. and C.G. Xie. Effect of Ligustrazine on macrophage infiltration and expression of MCP-1 and ICAM-1 in diabetic rats. Lishizhen Med. Mater. Med. Res. 20: 275-277, 2009.
40. Yang, Y., C.G. Xie and Y.J. Du. Effect of Ligustrazine on the expression of connective tissue growth factor and osteopontin in the tubulointerstitium of diabetic nephropathy rats. Tradit. Chin. Drug Res. Clin. Pharmacol. 19: 106-109, 2008.
41. Yang, Y. and P. Xiong. Effect of Ligustrazine injection on blood glucose, urine protein and C reactive protein of patients with diabetic nephropathy. Jiangsu J. Tradit. Chin. Med. 40: 34-35, 2008.
42. Yang, Y.S., Z.X. Yang and Y.H. Guo. Clinical observation on the therapeutic effect of Ligustrazine injection in early diabetic nephropathy. Hebei Med. J. 29: 983, 2007.
43. Yu, H.H. Effect of Ligustrazine in early diabetic nephropathy. Clin. Med. 18: 31-32, 1998.
44. Zeng, J.Y., Z.M. Luo and J.L. Zhang. Clinical observation on the therapeutic effect of Ligustrazine injection in diabetic nephropathy. Guangdong Med. J. 26: 1004-1005, 2005.
45. 2 microglobulin in patients with diabetic nephropathy. Guangming J. Chin. Med. 25: 1641-1642, 2010.
46. Zhao, X.Z. Clinical observation on the therapeutic effect of Ligustrazine injection in early diabetic nephropathy. J. Med. Forum 25: 31-33, 2004.
47. Zhou, C.Q., H. Xie and M. Zhou. Clinical observation on the therapeutic effect of Ligustrazine injection in diabetic nephropathy. China Foreign Med. J. 7: 71-72, 2009.
48. Zou, L.Y., X.M. Hao, G.Q. Zhang, M. Zhang, J.H. Guo and T.F. Liu. Effect of tetramethyl pyrazine on L-type calcium channel in rat ventricular myocytes. Can. J. Physiol. Pharm. 79: 621-626, 2001. (Pubitemid 32747872)